Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03711162
Registration number
NCT03711162
Ethics application status
Date submitted
15/10/2018
Date registered
18/10/2018
Titles & IDs
Public title
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
Query!
Secondary ID [1]
0
0
2018-001405-87
Query!
Secondary ID [2]
0
0
GLPG1690-CL-303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ISABELA1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GLPG1690
Treatment: Drugs - Placebo
Experimental: GLPG1690 600 mg - Participants received GLPG1690 (ziritaxestat) 600 mg, film-coated tablets orally once daily (mean GLPG1690 exposure was up to 325.3 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
Experimental: GLPG1690 200 mg - Participants received GLPG1690 (ziritaxestat) 200 mg as film-coated tablet for oral use once daily (mean GLPG1690 exposure was up to 356.0 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
Placebo comparator: Placebo - Participants received GLPG1690 (ziritaxestat) matching placebo tablets for oral use once daily (mean GLPG1690 exposure was up to 353.4 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
Treatment: Drugs: GLPG1690
GLPG1690, film-coated tablets for oral use.
Treatment: Drugs: Placebo
Matching placebo, film-coated tablets for oral use.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annual Rate of Decline in FVC up to Week 52
Query!
Assessment method [1]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [1]
0
0
Baseline up to week 52
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Disease Progression up to Week 52
Query!
Assessment method [1]
0
0
Disease progression was defined as the composite occurrence of more than or equal to (\>=)10 percent (%) absolute decline in percent predicted forced vital capacity (%FVC) or all-cause mortality. FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [1]
0
0
Up to week 52
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS)
Query!
Assessment method [2]
0
0
Percentage of participants with respiratory related hospitalization were reported in this measure.
Query!
Timepoint [2]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [3]
0
0
Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Query!
Assessment method [3]
0
0
SGRQ is a 50-item paper questionnaire designed to measure and quantify the impact of chronic respiratory disease on health-related quality of life (QOL) and well-being, split into 3 domains: symptoms score assessing the frequency and severity of respiratory symptoms (Items 1-8), activity score assessing the effects of breathlessness on mobility and physical activity (Items 11-17 and 36 to 44), and impacts score assessing the psychosocial impact of the disease (Items 9-10, 18-35 and 45-50). Each item has a specific weight.
Domain scores = 100 \* summed weights from positive items in that component/sum of maximum weights for all non-missing items in that component
Total score = 100 \* summed weights from positive items in the questionnaire/sum of maximum weights for all non-missing items in the questionnaire
Scores were weighted such that each domain score ranged from 0 to 100 and the total score ranged from 0 to 100, with higher scores indicating the poorer health-related QOL.
Query!
Timepoint [3]
0
0
Baseline, week 52
Query!
Secondary outcome [4]
0
0
Annual Rate of Decline in FVC Until EoS
Query!
Assessment method [4]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [4]
0
0
Baseline up to EoS (week 121)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Disease Progression Until EoS
Query!
Assessment method [5]
0
0
Disease progression was defined as the composite occurrence of \>=10% absolute decline in percent predicted %FVC or all-cause mortality. FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [5]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [6]
0
0
Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 100
Query!
Assessment method [6]
0
0
SGRQ is a 50-item paper questionnaire designed to measure and quantify the impact of chronic respiratory disease on health-related quality of life (QOL) and well-being, split into 3 domains: symptoms score assessing the frequency and severity of respiratory symptoms (Items 1-8), activity score assessing the effects of breathlessness on mobility and physical activity (Items 11-17 and 36 to 44), and impacts score assessing the psychosocial impact of the disease (Items 9-10, 18-35 and 45-50). Each item has a specific weight.
Domain scores = 100 \* summed weights from positive items in that component/sum of maximum weights for all non-missing items in that component Total score = 100 \* summed weights from positive items in the questionnaire/sum of maximum weights for all non-missing items in the questionnaire Scores were weighted such that each domain score ranged from 0 to 100 and the total score ranged from 0 to 100, with higher scores indicating the poorer health-related QOL.
Query!
Timepoint [6]
0
0
Baseline, week 100
Query!
Secondary outcome [7]
0
0
Percentage of Participants With All Cause Hospitalization Until EoS
Query!
Assessment method [7]
0
0
Percentage of participants with all cause hospitalization was reported for this measure.
Query!
Timepoint [7]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Respiratory Related Mortality Until EoS
Query!
Assessment method [8]
0
0
Percentage of participants with respiratory related mortality until EoS were reported for this study.
Query!
Timepoint [8]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [9]
0
0
Percentage of Participants Hospitalized for Non-elective Lung Transplant Until EoS
Query!
Assessment method [9]
0
0
Percentage of Participants who were hospitalized for Non-elective lung transplant were reported for this measure.
Query!
Timepoint [9]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation Until EoS
Query!
Assessment method [10]
0
0
Percentage of participants with acute IPF exacerbation until EoS were reported for this measure.
Query!
Timepoint [10]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [11]
0
0
Percentage of Participants With All Cause Mortality or Hospitalization for Non-elective Lung Transplant Until EoS
Query!
Assessment method [11]
0
0
Percentage of participants with all-cause mortality or hospitalization for non-elective lung transplant were reported for this measure.
Query!
Timepoint [11]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [12]
0
0
Percentage of Participants With All Cause Mortality, Hospitalization for Non-elective Lung Transplant or Hospitalization for Qualifying for Lung Transplant Until EoS
Query!
Assessment method [12]
0
0
Percentage of participants with all-cause mortality or hospitalization for non-elective lung transplant or hospitalization for qualifying for lung transplant were reported for this measure.
Query!
Timepoint [12]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [13]
0
0
Percentage of Participants With All-Cause Mortality or Hospitalization That Meets >=10% Absolute Decline in %FVC or Respiratory-Related Hospitalization Until EoS
Query!
Assessment method [13]
0
0
Percentage of participants with all-cause mortality or respiratory related hospitalization that meets \>=10% absolute decline in %FVC or respiratory-related hospitalization were reported for this measure.
Query!
Timepoint [13]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [14]
0
0
Percentage of Participants With All-Cause Mortality or Respiratory-Related Hospitalizations Until EoS
Query!
Assessment method [14]
0
0
Percentage of participants with all-cause mortality or respiratory related hospitalization were reported for this measure.
Query!
Timepoint [14]
0
0
Up to EoS (week 121)
Query!
Secondary outcome [15]
0
0
FVC at Week 52
Query!
Assessment method [15]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [15]
0
0
Week 52
Query!
Secondary outcome [16]
0
0
Change From Baseline in FVC at Week 52
Query!
Assessment method [16]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [16]
0
0
Baseline, week 52
Query!
Secondary outcome [17]
0
0
Percent Change From Baseline in FVC at Week 52
Query!
Assessment method [17]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [17]
0
0
Baseline, week 52
Query!
Secondary outcome [18]
0
0
FVC at Week 112
Query!
Assessment method [18]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [18]
0
0
Week 112
Query!
Secondary outcome [19]
0
0
Change From Baseline in FVC at Week 112
Query!
Assessment method [19]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [19]
0
0
Baseline, week 112
Query!
Secondary outcome [20]
0
0
Percent Change From Baseline in FVC at Week 112
Query!
Assessment method [20]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [20]
0
0
Baseline, week 112
Query!
Secondary outcome [21]
0
0
Percentage of Participants With Absolute Categorical Change From Baseline in Percent FVC at Week 52: FVC Change Within =5
Query!
Assessment method [21]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [21]
0
0
Baseline, week 52
Query!
Secondary outcome [22]
0
0
Percentage of Participants With Absolute Categorical Change From Baseline in Percent FVC at Week 112: FVC Change Within =5
Query!
Assessment method [22]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [22]
0
0
Baseline, week 112
Query!
Secondary outcome [23]
0
0
Percentage of Participants With Absolute Categorical Change From Baseline in Percent FVC at Week 52: FVC Change Within =10
Query!
Assessment method [23]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [23]
0
0
Baseline, week 52
Query!
Secondary outcome [24]
0
0
Percentage of Participants With Absolute Categorical Change From Baseline in Percent FVC at Week 112: FVC Change Within =10
Query!
Assessment method [24]
0
0
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Query!
Timepoint [24]
0
0
Baseline, week 112
Query!
Secondary outcome [25]
0
0
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Query!
Assessment method [25]
0
0
Safety was assessed by AEs, which included abnormalities identified during a medical test (example, laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study drug or was clinically significant. A Treatment emergent AE (TEAE) was defined as any AE that started or worsened after the first dose of study drug up to 30 days after the last dose of study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization.
Query!
Timepoint [25]
0
0
Baseline up to 30 days after the last dose (up to week 121)
Query!
Secondary outcome [26]
0
0
Changes From Baseline Leicester Cough Questionnaire (LCQ) Total Score and Individual Domain Score at Week 52 and Week 100
Query!
Assessment method [26]
0
0
Cough was evaluated using the LCQ. The LCQ was a 19-item questionnaire split into three domains: physical, psychological, and social. Scores were calculated by domain (range from 1 to 7, higher scores indicated a better health status) and then the total score was calculated by adding the individual domain score. Total score ranged from 3 to 21, with higher scores indicated a better health status.
Query!
Timepoint [26]
0
0
Baseline, week 52, week 100
Query!
Secondary outcome [27]
0
0
Change From Baseline in Visual Analogue Score (VAS): Cough at Week 52 and Week 100
Query!
Assessment method [27]
0
0
Cough was assessed using VAS score, ranged from 0 (no cough) to 100 millimeter (mm) (worst possible cough).
Query!
Timepoint [27]
0
0
Baseline, week 52, week 100
Query!
Secondary outcome [28]
0
0
Change From Baseline in Visual Analogue Score (VAS): Urge to Cough at Week 52 and Week 100
Query!
Assessment method [28]
0
0
Urge to Cough was assessed using VAS score, ranged from 0 (no urge to cough) to 100 mm (highest urge to cough).
Query!
Timepoint [28]
0
0
Baseline, week 52, week 100
Query!
Secondary outcome [29]
0
0
Change From Baseline in European Quality Of Life (EQ) VAS at Week 52 and Week 100
Query!
Assessment method [29]
0
0
EuroQol outcome measurements is a printed 20 cm VAS that appears somewhat like a thermometer, on which a score from 0 (worst imaginable health state or death) to 100 (best imaginable health state) was marked by the participant (or, when necessary, their proxy) with the scale in view.
Query!
Timepoint [29]
0
0
Baseline, week 52, week 100
Query!
Secondary outcome [30]
0
0
Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) at Week 52 and Week 100
Query!
Assessment method [30]
0
0
The K-BILD questionnaire was specifically developed to analyze the health status of participants with ILD. The questionnaire consists of 15 items (assessed by the participants on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). To score the K-BILD, the Likert response scale weightings for individual items are combined and scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status).
Query!
Timepoint [30]
0
0
Baseline, week 52, week 100
Query!
Secondary outcome [31]
0
0
Area Under The Concentration Time Curve (AUC) of Ziritaxtestat
Query!
Assessment method [31]
0
0
Area under the concentration time curve of ziritaxtestat was reported.
Query!
Timepoint [31]
0
0
Sparse samples collected on day 1 pre-dose, day 85 post-dose, day 237 post-dose, day 183 pre-dose, day 365 pre-dose
Query!
Secondary outcome [32]
0
0
Maximum Observed Plasma Concentration (Cmax) of Ziritaxtestat
Query!
Assessment method [32]
0
0
Maximum Observed Plasma Concentration of Ziritaxtestat was reported.
Query!
Timepoint [32]
0
0
Sparse samples collected on day 1 pre-dose, day 85 post-dose, day 237 post-dose, day 183 pre-dose, day 365 pre-dose
Query!
Secondary outcome [33]
0
0
Change From Baseline in Total Distance Walked in Six-minute Walk Test (6MWT) at Week 52 and Week 100
Query!
Assessment method [33]
0
0
The 6-MWT depicted the total distance covered by a participant during 6 minutes of walking.
Query!
Timepoint [33]
0
0
Baseline, week 52, week 100
Query!
Secondary outcome [34]
0
0
Change From Baseline in Diffusing Capacity of Lung for Carbon Monoxide (DLCO) (Corrected for Hemoglobin [Hb]) at Week 52 and Week 100
Query!
Assessment method [34]
0
0
Change from baseline in DLCO (percent predicted hemoglobin level corrected) was reported for this measure.mmol/min/kPa: Millimole per minute per kilopascal
Query!
Timepoint [34]
0
0
Baseline, week 52, week 100
Query!
Eligibility
Key inclusion criteria
* Male or female subject aged =40 years on the day of signing the Informed Consent Form (ICF).
* A diagnosis of IPF within 5 years prior to the screening visit, as per applicable American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) guidelines at the time of diagnosis.
* Chest high-resolution computed tomography (HRCT) historically performed within 12 months prior to the screening visit and according to the minimum requirements for IPF diagnosis by central review based on subject's HRCT only (if no lung biopsy (LB) available), or based on both HRCT and LB (with application of the different criteria in either situation). If an evaluable HRCT <12 months prior to screening is not available, an HRCT can be performed at screening to determine eligibility, according to the same requirements as the historical HRCT.
* Subjects receiving local standard of care for the treatment of IPF, defined as either pirfenidone or nintedanib at a stable dose for at least two months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason). A stable dose is defined as the highest dose tolerated by the subject during those two months.
* The extent of fibrotic changes is greater than the extent of emphysema on the most recent HRCT scan (investigator-determined).
* Meeting all of the following criteria during the screening period: FVC =45% predicted of normal, Forced expiratory volume in 1 second (FEV1)/FVC =0.7, diffusing capacity of the lung for carbon monoxide (DLCO) corrected for Hb =30% predicted of normal.
* Estimated minimum life expectancy of at least 30 months for non IPF related disease in the opinion of the investigator.
* Male subjects and female subjects of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of first dose of investigational medicinal product (IMP) (for the male subject) or the signing of the ICF (for the female subject), during the study, and until 90 days (male) or 30 days (female) after the last dose of IMP.
* Able to walk at least 150 meters during the 6-Minute Walk Test (6MWT) at screening Visit 1; without having a contraindication to perform the 6MWT or without a condition putting the subject at risk of falling during the test (investigator's discretion). The use of a cane is allowed, the use of a stroller is not allowed at all for any condition. At Visit 2, for the oxygen titration test, resting oxygen saturation (SpO2) should be =88% with maximum 6 L O2/minute; during the walk, SpO2 should be =83% with 6 L O2/minute or =88% with 0, 2 or 4 L O2/minute.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of malignancy within the past 5 years (except for carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin that has been treated with no evidence of recurrence, prostate cancer that has been medically managed through active surveillance or watchful waiting, squamous cell carcinoma of the skin if fully resected, and Ductal Carcinoma In Situ).
* Clinically significant abnormalities detected on ECG of either rhythm or conduction, a QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 ms, or a known long QT syndrome. Patients with implantable cardiovascular devices (e.g. pacemaker) affecting the QT interval time may be enrolled in the study based upon investigator judgment following cardiologist consultation if deemed necessary, and only after discussion with the medical monitor.
* Acute IPF exacerbation within 6 months prior to screening and/or during the screening period. The definition of an acute IPF exacerbation is as follows: Previous or concurrent diagnosis of IPF; Acute worsening or development of dyspnea typically < 1 month duration; Computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern and deterioration not fully explained by cardiac failure or fluid overload.
* Lower respiratory tract infection requiring treatment within 4 weeks prior to screening and/or during the screening period.
* Interstitial lung disease associated with known primary diseases (e.g. sarcoidosis and amyloidosis), exposures (e.g. radiation, silica, asbestos, and coal dust), or drugs (e.g. amiodarone).
* Diagnosis of severe pulmonary hypertension (investigator- determined).
* Unstable cardiovascular, pulmonary (other than IPF), or other disease within 6 months prior to screening or during the screening period (e.g. acute coronary disease, heart failure, and stroke).
* Had gastric perforation within 3 months prior to screening or during screening, and/or underwent major surgery within 3 months prior to screening, during screening or have major surgery planned during the study period.
* History of nintedanib-related increase in ALT and/or AST of >5 x upper limit of the normal range (ULN) and increased susceptibility to elevated LFT; moderate to severe hepatic impairment (Child-Pugh B or C) and/or abnormal liver function test (LFT) at screening, defined as aspartate aminotransferase (AST), and/or alanine aminotransferase (ALT), and/or total bilirubin =1.5 x upper limit of the normal range (ULN), and/or gamma glutamyl transferase (GGT) =3 x ULN. Retesting is allowed once for abnormal LFT.
* Abnormal renal function defined as estimated creatinine clearance, calculated according to Cockcroft-Gault calculation (CCr) <30 mL/min. Retesting is allowed once.
* Use of any of the following therapies within 4 weeks prior to screening and during the screening period, or planned during the study: warfarin, imatinib, ambrisentan, azathioprine, cyclophosphamide, cyclosporine A, bosentan, methotrexate, sildenafil (except for occasional use), prednisone at steady dose >10 mg/day or equivalent.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/11/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/03/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
525
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [3]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [4]
0
0
Corte Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [5]
0
0
Lung Research Queensland - Chermside
Query!
Recruitment hospital [6]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [7]
0
0
St Vincent's Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [8]
0
0
Austin Health - Heidelberg
Query!
Recruitment hospital [9]
0
0
Respiratory Clinical Trials Pty Ltd - Kent Town
Query!
Recruitment hospital [10]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
VIC 3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
NSW 2050 - Camperdown
Query!
Recruitment postcode(s) [5]
0
0
QLD 4060 - Chermside
Query!
Recruitment postcode(s) [6]
0
0
NSW 2139 - Concord
Query!
Recruitment postcode(s) [7]
0
0
NSW 2010 - Darlinghurst
Query!
Recruitment postcode(s) [8]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [9]
0
0
SA 5067 - Kent Town
Query!
Recruitment postcode(s) [10]
0
0
VIC 3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Rhode Island
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Wisconsin
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Antwerp
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Brussels
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Leuven
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Yvoir
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Porto Alegre
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Santo André
Query!
Country [36]
0
0
Chile
Query!
State/province [36]
0
0
Concepción
Query!
Country [37]
0
0
Chile
Query!
State/province [37]
0
0
Curicó
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
Quillota
Query!
Country [39]
0
0
Chile
Query!
State/province [39]
0
0
Santiago
Query!
Country [40]
0
0
Chile
Query!
State/province [40]
0
0
Talca
Query!
Country [41]
0
0
Chile
Query!
State/province [41]
0
0
Valparaíso
Query!
Country [42]
0
0
Chile
Query!
State/province [42]
0
0
Viña Del Mar
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Brno
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Ostrava
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Aarhus
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Hellerup
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Odense
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Bad Berka
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Berlin
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Coswig
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Hannover
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Heidelberg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Leipzig
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Rosenheim
Query!
Country [56]
0
0
Greece
Query!
State/province [56]
0
0
Athens
Query!
Country [57]
0
0
Greece
Query!
State/province [57]
0
0
Iraklio
Query!
Country [58]
0
0
Greece
Query!
State/province [58]
0
0
Larissa
Query!
Country [59]
0
0
Greece
Query!
State/province [59]
0
0
Thessaloníki
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Hamamatsu
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Kumamoto
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Sakai
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Seto
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Tokyo
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Yokohama
Query!
Country [66]
0
0
Peru
Query!
State/province [66]
0
0
Chancay
Query!
Country [67]
0
0
Peru
Query!
State/province [67]
0
0
Lima Cercado
Query!
Country [68]
0
0
Peru
Query!
State/province [68]
0
0
Lima
Query!
Country [69]
0
0
Peru
Query!
State/province [69]
0
0
San Isidro
Query!
Country [70]
0
0
Peru
Query!
State/province [70]
0
0
San Miguel
Query!
Country [71]
0
0
Peru
Query!
State/province [71]
0
0
Santiago De Surco
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Pontevedra
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Barcelona
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Pamplona
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Santander
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Valencia
Query!
Country [78]
0
0
Taiwan
Query!
State/province [78]
0
0
Kaohsiung City
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
New Taipei City
Query!
Country [80]
0
0
Taiwan
Query!
State/province [80]
0
0
Taipei
Query!
Country [81]
0
0
Turkey
Query!
State/province [81]
0
0
Istanbul
Query!
Country [82]
0
0
Turkey
Query!
State/province [82]
0
0
Izmir
Query!
Country [83]
0
0
Turkey
Query!
State/province [83]
0
0
Mersin
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Birmingham
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Bristol
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Cambridge
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Cottingham
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Exeter
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Liverpool
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
London
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Manchester
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Newcastle
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Nottingham
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Galapagos NV
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
Query!
Trial website
https://clinicaltrials.gov/study/NCT03711162
Query!
Trial related presentations / publications
Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W, Wijsenbeek M. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respir Res. 2019 May 21;6(1):e000422. doi: 10.1136/bmjresp-2019-000422. eCollection 2019.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Galapagos Study Director, MD
Query!
Address
0
0
Galapagos NV
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/62/NCT03711162/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/62/NCT03711162/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03711162